Browsing by Author "Soon, NC"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease(Hindawi Ltd, 2018) ;Kosasih, S ;Qin, WZ ;Rani, RA ;Abd Hamid, N ;Soon, NC ;Shah, SA ;Yaakob, YAli, RARBackgrounds. The aim of this study was to appraise the relationship between serum fragmented cytokeratin-18(CK-18), controlled attenuation parameter (CAP), and liver steatosis assessed by ultrasound (US) in nonalcoholic fatty liver disease (NAFLD) patients. Methods. Patients who underwent abdominal US were recruited, followed with measurement of CAP using Fibroscan 5 and serum fragmented CK-18 using enzyme-linked immunosorbent assay. The degree of liver steatosis assessed by US was categorized into mild (S1), moderate (S2), and severe (S3). Results. A total of 109 patients were included in our study. CAP and fragmented CK-18 level were significantly correlated with liver steatosis grade with r(s) = 0.56 and 0.68, p=0.001, respectively. NAFLD Fibrosis Score was poorly correlated with liver steatosis grade (r(s)=-0.096, p=0.318). Using fragmented CK-18 level, area under receiver operating characteristic (AUROC) curves for S >= 2 and S >= 3 were excellent (0.82 and 0.84, respectively). Using CAP, AUROC curves for detection of S >= 2 and S >= 3 were good (0.76, 0.77, respectively). We also proposed cut-off value of CAP to detect S >= 2 and S >= 3 to be 263 and 319 db/m, respectively, and fragmented CK-18 level to detect S >= 2 and S >= 3 (194 and 294 U/L, respectively). Conclusions. Both the fragmented CK-18 level and the CAP, but not NAFLD Fibrosis Score, were well correlated with hepatic steatosis grade as assessed by US. - Some of the metrics are blocked by yourconsent settings
Publication Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus(Spandidos Publ Ltd, 2017) ;Loong, TH ;Soon, NC ;Mahmud, NRKN ;Naidu, J ;Rani, RA ;Hamid, NA ;Elias, MH ;Rose, IM ;Tamil, A ;Mokhtar, NMAli, RARThere is a lack of non-invasive screening modalities to diagnose chronic atrophic gastritis (CAG) and intestinal metaplasia (IM). Thus, the aim of the present study was to determine the sensitivity and specificity of serum pepsinogen I (PGI), PGI: II, the PGI: II ratio and gastrin-17 (G-17) in diagnosing CAG and IM, and the correlations between these serum biomarkers and pre-malignant gastric lesions. A cross-sectional study of 72 patients (82% of the calculated sample size) who underwent oesophagealgastro-duodenos-copy for dyspepsia was performed in the present study. The mean age of the participants was 56.2 +/- 16.2 years. Serum PGI: I, PGI: II, G-17 and Helicobacter pylori antibody levels were measured by enzyme-linked immunosorbent assay. Median levels of PGI: I, PGI: II, the PGI: II ratio and G-17 for were 129.9 mu g/l, 10.3 mu g/l, 14.7 and 4.4 pmol/l, respectively. Subjects with corpus CAG/IM exhibited a significantly lower PGI: II ratio (7.2) compared with the control group (15.7; P< 0.001). Histological CAG and IM correlated well with the serum PGI: II ratio (r=-0.417; P<0.001). The cut-off value of the PGI: II ratio of <= 10.0 demonstrated high sensitivity (83.3%), specificity (77.9%) and area under the receiver operating characteristic curve of 0.902 in detecting the two conditions. However, the sensitivity was particularly low at a ratio of <= 3.0. The serum PGI: II ratio is a sensitive and specific marker to diagnose corpus CAG/IM, but at a high cut-off value. This ratio may potentially be used as an outpatient, non-invasive biomarker for detecting corpus CAG/IM.